This clinical finding, however, differed from preclinical results that documented inhibition of Pten-null prostate cancer when pharmacologic inhibitors of AR and PI3K/mTORC1 or AKT activity were used concurrently [16, 17, 33]. This evidence concerns the gene AKT1 and prostate cancer.